Cagr 10mg+Sema 10mg: What research findings exist regarding weight loss and weight management combinations?
At week 68, CagriSema had an average weight loss of 18.4%, semaglutide group 11.9%. Another study reports: CagriSema group average weight loss 20.4%, placebo 3.0%, directly supporting the weight loss effect of combination study drug.[1] ↗ [2] ↗
Currently, 3 original studies related to the theme of this page have been selected. The number of studies includes different designs, populations, or preparations, not commercial clinical efficacy ratings. This page is a usage-oriented positive data selection, not a systematic review or dosing recommendation. Historical studies, combination preparations, and special models are all separately indicated.
Comparison of study design and results
Results from different populations, species, materials, or follow-up times cannot be directly combined. The table below is a comparative summary of published data, not new experimental data.
| Literature | Study subjects and design | Observation and discovery | Scope of Explanation |
|---|---|---|---|
| 2026 · PMID 42009015 | Human Phase III randomized; Japan/Taiwan REDEFINE-5 | At week 68, CagriSema had an average weight loss of 18.4%, semaglutide group 11.9%. | Specific combinations, formulations, and inclusion criteria; three packaging specifications share literature, not three separate studies. |
| 2025 · PMID 40544433 | REDEFINE1; 3,417 non-diabetic overweight or obese adults; 68-week randomized controlled trial | The CagriSema group had an average weight loss of 20.4%, placebo 3.0%, directly supporting the weight loss effect of the combined study formulation. | Includes lifestyle interventions; specific combined ratios are not equivalent to study formulations in the listed product; gastrointestinal adverse events were relatively common. |
| 2025 · PMID 40544432 | REDEFINE2; 1,206 overweight or obese adults with type 2 diabetes; 68 weeks | The CagriSema group had an average weight loss of 13.7%, placebo 3.4%, with weight as the primary endpoint. | Limited to populations with combined diabetes and study combination formulations; does not prove equivalence of different ratios or commercial batches. |
References
How does the combination therapy in Japan and Taiwan compare directly with monotherapy?
At week 68, CagriSema had an average weight loss of 18.4%, semaglutide group 11.9%.[1] ↗
Human Phase III randomized; Japan/Taiwan REDEFINE-5
Specific combinations, formulations, and inclusion criteria; three packaging specifications share literature, not three separate studies.
View the Article Title and Full Citation＋
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.
The Lancet. Diabetes & Endocrinology · Volume and issue year 2026
First published 2026-04-17 · PMID 42009015
DOI 10.1016/S2213-8587(25)00402-4
What are the findings of the CagriSema weight loss trial in non-diabetic populations?
The CagriSema group had an average weight loss of 20.4%, placebo 3.0%, directly supporting the weight loss effect of the combined study formulation.[2] ↗
REDEFINE1; 3,417 non-diabetic overweight or obese adults; 68-week randomized controlled trial
Includes lifestyle interventions; specific combined ratios are not equivalent to study formulations in the listed product; gastrointestinal adverse events were relatively common.
View the Article Title and Full Citation＋
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
The New England Journal of Medicine · Volume, Issue, Year 2025
First published 2025-06-22 · PMID 40544433
DOI 10.1056/NEJMoa2502081
What are the CagriSema weight results in populations with diabetes?
The CagriSema group had an average weight loss of 13.7%, placebo 3.4%, with weight as the primary endpoint.[3] ↗
REDEFINE2; 1,206 overweight or obese adults with type 2 diabetes; 68 weeks
Limited to populations with combined diabetes and study combination formulations; does not prove equivalence of different ratios or commercial batches.
View the Article Title and Full Citation＋
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.
The New England Journal of Medicine · Volume, Issue, Year 2025
First published 2025-06-22 · PMID 40544432
DOI 10.1056/NEJMoa2502082
Common issues and corresponding evidence
Cagr 10mg+Sema 10mg: What research findings exist regarding weight loss and weight management combinations?＋
At week 68, CagriSema had an average weight loss of 18.4%, semaglutide group 11.9%. Another study reports: CagriSema group average weight loss 20.4%, placebo 3.0%, directly supporting the weight loss effect of combination study drug.[1] ↗ [2] ↗
Does combining 10mg each imply a stronger weight loss effect?＋
: Cannot infer based on total bottle content. CagriSema results are limited to the trial formula and protocol; package specifications do not correspond to effect size and do not provide personal dosing recommendations.[2] ↗ [3] ↗ [1] ↗
Cagr 10mg+Sema 10mg—these conclusions apply to which study populations?＋
Human Phase III randomized; Japan/Taiwan REDEFINE-5; REDEFINE1; 3,417 non-diabetic overweight or obese adults; 68-week randomized controlled; REDEFINE2; 1,206 overweight or obese adults with type 2 diabetes; 68 weeks. Specific combinations, formulations, and inclusion criteria; three packaging specifications share literature, not three separate studies.[1] ↗ [2] ↗ [3] ↗
Cagr 10mg+Sema 10mg
Return to catalog specifications and batch file verification entry.
